Investment Rating - The report gives a "Buy" rating for the company, with a target price of 23.37 CNY based on a PE valuation of 57 times for 2026 [3][6]. Core Insights - The company is expected to benefit from a dual-driven strategy of traditional Chinese medicine (TCM) and chemical drugs, with a gradual clearance of the impact from centralized procurement on TCM business. The innovative drug pipeline is entering a harvest phase, with projected net profits for 2025-2027 being 290 million, 350 million, and 410 million CNY respectively, corresponding to EPS of 0.34, 0.41, and 0.48 CNY [3][9]. Summary by Sections 1. Dual-Driven Strategy of TCM and Chemical Drugs - The company has a rich product layout and maintains stable performance, with a focus on TCM and high-end generic drugs. The revenue from TCM has historically contributed over 50% of total revenue, while the share of chemical drugs has increased from 24% in 2016 to 36% in 2024 [13][16]. - The company launched an employee stock ownership plan in 2024 to incentivize core personnel, focusing on performance assessment and innovative drug development [23][24]. 2. Innovative Product Data and Growth Potential - The company has several innovative products entering commercialization or late-stage clinical trials. Notably, RAY1225, a dual-target drug for obesity and diabetes, has shown superior efficacy in clinical trials compared to existing treatments [27][29]. - ZSP1601, a first-in-class drug for NASH, is currently in IIb phase clinical trials and has demonstrated promising results in reducing liver inflammation markers [45][49]. 3. Core TCM Products and Market Recovery - The company's core TCM product, Compound Thrombus Tong Capsule, has maintained a leading market share in the ophthalmic TCM sector. As the impact of centralized procurement diminishes, sales are expected to stabilize and recover [9][18]. - The Brain Thrombus Capsule, another key product, has shown stable clinical demand and is projected to continue its steady growth [9][18].

Investment Rating - The report gives a "Buy" rating for the company, with a target price of 23.37 CNY based on a PE valuation of 57 times for 2026 [3][6]. Core Insights - The company is expected to benefit from a dual-driven strategy of traditional Chinese medicine (TCM) and chemical drugs, with a gradual clearance of the impact from centralized procurement on TCM business. The innovative drug pipeline is entering a harvest phase, with projected net profits for 2025-2027 being 290 million, 350 million, and 410 million CNY respectively, corresponding to EPS of 0.34, 0.41, and 0.48 CNY [3][9]. Summary by Sections 1. Dual-Driven Strategy of TCM and Chemical Drugs - The company has a rich product layout and maintains stable performance, with a focus on eye care, cardiovascular, respiratory, and digestive diseases. Revenue for the first three quarters of 2025 was 1.89 billion CNY, a decrease of 1.0% year-on-year, while net profit attributable to the parent company was 250 million CNY, an increase of 68.4% [13][9]. - The core TCM product, Compound Thrombus-Relieving Capsule, is a unique original formulation with a leading market share in the domestic ophthalmic TCM sector. The impact of centralized procurement is gradually being digested, and sales are expected to stabilize [9][10]. 2. Innovative Product Data and Growth Potential - The company has multiple innovative products entering commercialization or late-stage clinical trials. The PB2-targeted RNA polymerase inhibitor, Anladiwei Tablets, was approved in May 2025 for treating adult uncomplicated influenza, showing competitive advantages over Oseltamivir [9][27]. - The GLP-1/GIP dual-target drug RAY1225 for obesity and diabetes has entered Phase III clinical trials, with promising results indicating better weight loss efficacy compared to existing treatments [27][29]. 3. Financial Forecast and Investment Recommendations - The company’s revenue is projected to recover, with expected revenues of 2.803 billion, 3.126 billion, and 3.447 billion CNY for 2025, 2026, and 2027 respectively, reflecting growth rates of 13.6%, 11.5%, and 10.3% [5]. - The report emphasizes the importance of innovation and performance assessment, with an employee stock ownership plan launched in 2024 to incentivize core personnel [23][24].

Group 1 - The company announced a licensing agreement for the RAY1225 injection project, allowing Qilu Pharmaceutical to produce and commercialize the drug in China, while the company retains all rights outside of China [1] - The total payment for the licensing agreement is 1 billion yuan, which includes an upfront payment of 200 million yuan and milestone payments up to 800 million yuan, along with a double-digit percentage of net sales after the product launch [1] - RAY1225 is an innovative peptide drug with global intellectual property rights, showing promising results in clinical trials for weight loss, with a weight reduction of 10.1%-15.1% after 24 weeks of treatment [2] Group 2 - The company is seeing initial success in its transformation with core products like the Compound Thrombus Tong series and Brain Thrombus Tong capsules selected for national and regional procurement, indicating a strategy of "volume for price" to maintain profitability [3] - The company has a pipeline of innovative drugs, including ZSP1601 for MASH and RAY1225 for weight loss, with several Phase III clinical trials completed [3] - The company expects revenue growth from 2.53 billion yuan in 2025 to 3 billion yuan in 2027, with net profit projections of 310 million yuan in 2025 and 570 million yuan in 2026, reflecting a significant turnaround [4]

Group 1: Zhongsheng Pharma - The core business of Zhongsheng Pharma has stabilized after experiencing centralized procurement, with innovative drug research and development gradually yielding results, particularly in respiratory and metabolic fields [2][4] - The company reported a revenue of 1.889 billion yuan for the first three quarters of 2025, a year-on-year decrease of 1.01%, while net profit attributable to shareholders increased by 68.40% to 251 million yuan [4] - The core products of traditional Chinese medicine have maintained stable growth post-collective procurement, with sales resilience supported by volume compensating for price reductions [4][5] - The innovative pipeline includes RAY1225 injection, a dual-target drug for weight loss and blood sugar reduction, which has shown positive results in clinical trials [5] Group 2: Medical Device Industry - The brain-computer interface (BCI) industry in China has achieved rapid development under policy support, with a focus on establishing a robust technological and industrial framework by 2027 [6][8] - The National Medical Products Administration held a meeting to discuss the advancement of BCI medical devices, emphasizing safety and effectiveness as primary considerations [17] - By 2030, the BCI industry aims to cultivate globally influential leading enterprises and a competitive industrial ecosystem, with significant advancements expected in technology and application [18]

Macro Research - The core viewpoint of the report indicates that the US economy showed resilience in Q3 2025, with a GDP growth rate of 4.3%, surpassing expectations of 3.3% and the previous value of 3.8% [3][20] - Key drivers of this resilience include strong personal consumption, increased public spending, and enhanced export contributions, with capital market wealth effects supporting consumer spending [3][20] - The report highlights a "K" shaped economic divergence, characterized by income disparities affecting consumption, varying business conditions between large and small enterprises, and differences in investment growth between new and old economies [4][21] Strategy Research - The report emphasizes that Chinese companies are entering a new phase of globalization, aiming to capture high-value segments of the global value chain [9][25] - It notes that the acceleration of Chinese enterprises going abroad is a strategic response to rising domestic costs and tightening external market access, which is essential for high-quality development [9][25] - The report predicts that the demand for capital goods in China will remain strong, driven by industrialization and infrastructure investment in emerging markets [11][27] Biopharmaceutical Research - The report discusses the release of the sixth batch of medical device procurement documents, indicating a moderate expected price drop and a favorable situation for domestic manufacturers to increase market share [13][29] - It provides specific data on the expected demand for various medical devices, highlighting the market shares of different companies in the procurement process [30][32] - The report maintains a "buy" rating for companies likely to benefit from the procurement, such as Lepu Medical and Mindray Medical [29][30]

Core Viewpoint - The company Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced that its innovative drug, Angladiwei Tablets (brand name: Anruiwei), has been included in the National Medical Insurance Directory for 2025, which is expected to enhance market promotion and sales potential for the product [1][2]. Group 1: Product Information - Angladiwei Tablets are the world's first targeted drug for the PB2 subunit of the influenza A virus RNA polymerase, approved for treating adult patients with uncomplicated influenza [2]. - The drug is characterized by rapid action, strong efficacy, and low resistance, providing a cost-effective and accessible treatment option for patients [2]. Group 2: Market Impact - The inclusion of Angladiwei Tablets in the National Medical Insurance Directory is anticipated to positively impact the company's long-term operational development and market presence [2]. - Other core products of the company, including Lai Ru Te Wei Tablets and various other formulations, continue to be listed in the National Medical Insurance Directory, supporting the company's overall product portfolio [1].

Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has successfully included its innovative drug, Anladiwei Tablets (brand name: Anruiwei), in the National Medical Insurance Directory for 2025, which is expected to enhance patient access to effective treatment for influenza [1] Group 1: Product Inclusion - Anladiwei Tablets is the first global drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, approved for the treatment of uncomplicated influenza in adults [1] - The drug is characterized by rapid action, strong efficacy, and low resistance, providing a significant option for patients suffering from influenza [1] - Other core products of the company, including Lai Ru Te Wei Tablets and various formulations, continue to be included in the National Medical Insurance Directory [1] Group 2: Market Impact - The inclusion of Anladiwei Tablets in the Class B category of the National Medical Insurance Directory is expected to benefit a larger patient population, offering economical, safe, and accessible medication options [1] - The drug was approved by the National Medical Products Administration in May 2025, marking a significant milestone for the company's respiratory pipeline [1]

Core Viewpoint - Zhongsheng Pharmaceutical's innovative drug, Angladiwei Tablets (brand name: Anruiwei), has been included in the National Medical Insurance Directory for the first time through national medical insurance negotiations [1] Group 1: Company Developments - The company announced that its core product, Lai Ru Te Wei Tablets, along with several other products, continues to be included in the National Medical Insurance Directory [1]

Core Viewpoint - Zhongsheng Pharmaceutical's innovative drug Angladewe Tablets (brand name: Anruiwei) has been included in the National Medical Insurance Directory for the first time through national medical insurance negotiations for 2025 [1] Group 1: Company Developments - The company announced that its core products, including Lai Ru Te Wei Tablets, Compound Thrombus Tong Capsules, Cerebral Thrombus Tong Capsules, Sucralfate Oral Suspension, Carboxymethyl Starch Oral Solution, and Nitazoxanide Eye Drops, have also been included in the National Medical Insurance Directory [1]

Group 1: Company Overview and Financial Performance - The company is a high-tech enterprise engaged in drug research, production, and sales, with a focus on continuous shareholder returns through cash dividends totaling over 2 billion CNY since its listing [4]. - The company has a diverse product pipeline covering major disease areas such as cardiovascular, respiratory, ophthalmology, and digestive diseases, ensuring steady growth in performance [4]. - The company has maintained R&D investment exceeding 8% of revenue for several years, with the last three years seeing R&D investment surpassing 10% of revenue [5]. Group 2: R&D and Product Development - The company actively conducts post-marketing evaluations of traditional Chinese medicine (TCM) products, enhancing their clinical application and driving sales growth [5]. - The company is advancing the revival of dormant TCM products, with several products expected to become new performance growth points [7]. - The company is exploring the development of classic TCM formulas and hospital preparations, leveraging national policies encouraging TCM innovation [7]. Group 3: New Drug Approvals and Clinical Trials - The new drug Angladiwe tablets have been approved for market, with a comprehensive marketing strategy focusing on academic ecosystem building and data-driven service upgrades [8][9]. - Angladiwe tablets are the first oral drug targeting the PB2 site of the RNA polymerase for treating influenza, showing strong efficacy and low resistance [10]. - The company is conducting clinical trials for Angladiwe granules aimed at children and adolescents, with promising results indicating effective symptom relief [13][15]. Group 4: Future Directions and Market Expansion - The company is committed to international collaboration for its innovative drugs, aiming to enhance global R&D capabilities and brand influence [20]. - The company is focusing on metabolic diseases and respiratory diseases, with ongoing clinical trials for innovative drugs like RAY1225 and ZSP1601, which show promising efficacy and safety [16][17][18]. - The company is exploring various potential drug development pathways, including GLP-1 receptor agonists and multi-target therapies, to meet unmet clinical needs [19].